Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avadomide + Obinutuzumab in R/R DLBCL and Indolent NHL
NCT02417285Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of avadomide in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Celgene Corporation. Primary endpoint: Adverse Events (AEs). Started May 2015; status: completed.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02417285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417285.